AU Patent

AU2017213541B2 — Combination therapy for the treatment of cancer

Assigned to Novartis AG · Expires 2019-01-24 · 7y expired

What this patent protects

1: \dar\Interwoven\NRPortbl\DCC\DAR\15500918_l.docx-10 08/2017 Abstract The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormo…

USPTO Abstract

1: \dar\Interwoven\NRPortbl\DCC\DAR\15500918_l.docx-10 08/2017 Abstract The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the P13K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017213541B2
Jurisdiction
AU
Classification
—
Expires
2019-01-24
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.